Pliant Therapeutics (PLRX) Total Current Liabilities (2019 - 2026)

Pliant Therapeutics (PLRX) has 8 years of Total Current Liabilities data on file, last reported at $10.4 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $10.4 million, down 63.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.4 million (down 63.27% YoY), and the FY2025 annual result was $16.4 million, down 50.73% from the prior year.
• Total Current Liabilities declined to $10.4 million in Q1 2026 per PLRX's latest filing, from $16.4 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $40.0 million in Q3 2024 and troughed at $10.4 million in Q1 2026.
• A 5-year average of $25.1 million and a median of $26.2 million in 2022 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2026: Total Current Liabilities jumped 106.3% in 2022, then slumped 63.27% in 2026.
• A 5-year view of Total Current Liabilities shows it stood at $23.9 million in 2022, then grew by 19.28% to $28.5 million in 2023, then advanced by 16.46% to $33.2 million in 2024, then slumped by 50.73% to $16.4 million in 2025, then tumbled by 36.7% to $10.4 million in 2026.
• Business Quant data shows PLRX's Total Current Liabilities at $10.4 million in Q1 2026, $16.4 million in Q4 2025, and $17.6 million in Q3 2025.